You are here

  • Home
  • Online First
  • Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer

Article metrics

Article menu

other Versions

Download PDFPDF
Original research
Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer

 

Online download statistics by month:

Online download statistics by month: January 2022 to March 2023

AbstractFullPdf
Jan 20224751510
Feb 2022457169
Mar 2022329129
Apr 202210844118
May 20223721613
Jun 2022430219
Jul 202220475
Aug 202223844
Sep 202223886
Oct 202224330
Nov 202220463
Dec 202214963
Jan 202330056
Feb 202330820
Mar 202311730
Total514816595